Burden of premenstrual dysphoric disorder on health-related quality of life

Journal of Women's Health

Volumn 17, Issue 1, 2008, Pages 113-121

  Yang, Min ^a   Wallenstein, Gene ^a   Hagan, Michael ^b   Guo, Amy ^b   Chang, Joanne ^b   Kornstein, Susan ^c  

^a QualityMetric Incorporated   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BACKACHE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MENTAL HEALTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PAIN ASSESSMENT; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; RISK; UNITED STATES;

ACTIVITIES OF DAILY LIVING; ADULT; ANXIETY; COST OF ILLNESS; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 38849184642     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0417     Document Type: Article

References (45)

1. American College of Obstetricians and Gynecologists (ACOG). Premenstrual syndrome. Washington, DC: ACOG, 2000, vol. 15.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
3. Frank E, Severino SK. Premenstrual dysphoric disorder: Facts and meanings. J Pract Psychiatry Behav Health 1995;1:20.
4. Hurt SW, Schnurr PP, Severino SK, et al. Late luteal phase dysphric disorder in 670 women evaluated for premenstrual complaints. Am J Psychiatry 1992;149:525.
5. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry 1997;58(Suppl 14):4.
6. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: Experience for the United States, United Kingdom, and France. J Womens Health Gend Based Med 1999;8:1043.
7. Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol 1987;30:367.
8. Logue CM, Moos RH. Perimenstrual symptoms: Prevalence and risk factors. Psychosom Med 1986:48:388.
9. Silva CM, Gigante DP, Carret ML, Fassa AG. [Population study of premenstrual syndrome.] Rev Saude Publica 2006;40:47.
10. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health 1982;72:1257.
11. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003;48:515.
12. Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the criteria used for identification of PMS. J Womens Health 2006;15:546.
13. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119.
14. Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med 1997;42:637.
15. Chawla A, Swindle R, Long S, Kennedy S, Sternfeld B. Premenstrual dysphoric disorder: Is there an economic burden of illness? Med Care 2002;40:1101.
16. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002;70:125.
17. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. J Reprod Med 1988;33:340.
18. Dean BB, Borenstein JE. A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome. J Occup Environ Med 2004;46:649.
19. Ekholm UB, Backstrom T. Influence of premenstrual syndrome on family, social life, and work performance. Int J Health Serv 1994;24:629.
20. Halbreich U, Borenstein JE, Pearlstein T, Kahn LS. The prevalence, impairment, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003;28:1.
21. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005;162:1171.
22. Robinson RL, Swindle RW. Premenstrual symptom severity: Impact on social functioning and treatment seeking behaviors. J Womens Health Gend Based Med 2000;9:757.
23. Borenstein JE, Chiou CF, Dean BB, Wong J, Wade S. Estimating direct and indirect costs of premenstrual syndrome. J Occup Enviorn Med 2005;47:26.
24. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473.
26. Ware JE Jr, Kosinski M, Gandek B. SF-36 Health survey: Manual & interpretation guide. Lincoln, RI: QualityMetric Incorporated, 2000.
27. Ware JE Jr, Kosinski M. SF-36 physical & mental health summary scales: A manual for users of version 1, 2nd ed. Lincoln, RI: QualityMetric Incorporated, 2001.
28. Barnard K, Frayne SM, Skinner KM, Sullivan LM. Health status among women with menstrual symptoms. J Womens Health 2003;12:911.
29. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-12 health survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Incorporated, 2002.
30. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Maruish ME. User's manual for the SF-36® health survey (version 2), 2nd ed. Lincoln, RI: QualityMetric Incorporated, 2007.
31. Zhang J, Quan H, Ng J, Stepanavage ME. Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997;18:204.
32. Lo IK, Litchfield RB, Griffin S, Faber K, Patterson SD, Kirkley A. Quality-of-life outcome following hemiarthroplasty or total shoulder arthroplasty in patients with osteoarthritis. A prospective, randomized trial. J Bone Joint Surg Am 2005;87:2178.
33. Mitchell C, Walker J, Walters S, Morgan AB, Binns T, Mathers N. Cost and effectiveness of pre- and post-operative home physiotherapy for total knee replacement: Randomized controlled trial. J Eval Clin Pract 2005;11:283.
34. Quintana JM, Escobar A, Arostegui I, et al. Health-related quality of life and appropriateness of knee or hip joint replacement. Arch Intern Med 2006;166:220.
35. Rabenda V, Burlet N, Ethgen O, Raeman F, Belaiche J, Reginster J-Y. A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2005;64:688.
36. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: Impact of disease and treatment response. Am J Manag Care 2002;8:231.
37. West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: A comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol 2005;24:117.
38. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28:39.
39. Endicott J, Amsterdam J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med 1999;8:663.
40. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414.
41. Yonkers KA, Brown C, Pearlstein TB, Foegh ML, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492.
42. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104:110.
43. Gehlert S, Hartlage S. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 1997;18:36.
44. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002;99:1014.
45. Steiner M, Macdougall M, Brown E. The premenstrual screening tool (PSST) for clinicians. Arch Womens Ment Health 2003;6:203.